Agios Pharmaceuticals (AGIO)
$
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
About
Business overview of Agios Pharmaceuticals (AGIO)
Agios Pharmaceuticals Inc is a biopharmaceutical company with a focus on developing treatments geared towards cancer and rare genetic disorders of metabolism. The company's primary focus is to develop potentially transformative small-molecule medicines. The clinical development plan for Agios' product candidates includes a precision approach with initial study designs that allow for genetically or biomarker-defined patient populations. The company seeks the potential for proof of concept early in clinical development, along with any potential for accelerated approval.
Key Insights
Critical company metrics and information
Share Price
$48.39Market Cap
$2.76 BillionTotal Outstanding Shares
57.03 Million SharesTotal Employees
386Dividend
No dividendIPO Date
July 24, 2013SIC Description
Pharmaceutical PreparationsHomepage
https://www.agios.com
Historical Stock Splits
Execution Date | Split Amount |
---|---|
No Historical Stock Splits |
Cash Flow Statement
October 1, 2023 to September 30, 2024
Metric | Value |
---|---|
Net Cash Flow From Investing Activities, Continuing | $508.11 Million |
Net Cash Flow From Financing Activities, Continuing | $10.45 Million |
Net Cash Flow | $189.40 Million |
Net Cash Flow From Investing Activities | $508.11 Million |
Net Cash Flow From Operating Activities, Continuing | $-329.16 Million |
Net Cash Flow From Operating Activities | $-329.16 Million |
Net Cash Flow, Continuing | $189.40 Million |
Net Cash Flow From Financing Activities | $10.45 Million |
Income Statement
October 1, 2023 to September 30, 2024
Metric | Value |
---|---|
Operating Income/Loss | $-406.98 Million |
Net Income/Loss Attributable To Parent | $674.31 Million |
Net Income/Loss Available To Common Stockholders, Basic | $674.31 Million |
Gross Profit | $29.38 Million |
Revenues | $32.87 Million |
Operating Expenses | $436.36 Million |
Income/Loss From Continuing Operations Before Tax | $727.43 Million |
Benefits Costs and Expenses | $-674.34 Million |
Selling, General, and Administrative Expenses | $140.39 Million |
Diluted Earnings Per Share | $11.66 |
Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
Costs And Expenses | $439.85 Million |
Diluted Average Shares | $115.12 Million |
Research and Development | $295.96 Million |
Income/Loss From Continuing Operations After Tax | $674.31 Million |
Cost Of Revenue | $3.49 Million |
Net Income/Loss | $674.31 Million |
Basic Average Shares | $113.62 Million |
Basic Earnings Per Share | $11.86 |
Preferred Stock Dividends And Other Adjustments | $0.00 |
Balance Sheet
October 1, 2023 to September 30, 2024
Metric | Value |
---|---|
Liabilities | $165.12 Million |
Current Liabilities | $119.45 Million |
Current Assets | $1.07 Billion |
Equity Attributable To Noncontrolling Interest | $0.00 |
Noncurrent Liabilities | $45.67 Million |
Other Non-current Assets | $705.79 Million |
Noncurrent Assets | $717.61 Million |
Other Current Liabilities | $84.62 Million |
Wages | $17.69 Million |
Assets | $1.79 Billion |
Accounts Payable | $17.14 Million |
Cash | $1.70 Billion |
Inventory | $26.43 Million |
Equity | $1.63 Billion |
Fixed Assets | $11.82 Million |
Equity Attributable To Parent | $1.63 Billion |
Liabilities And Equity | $1.79 Billion |
Historical Dividends
Announcement Date | Payment Date | Record Date | Amount | Frequency |
---|---|---|---|---|
No historical dividends |
Boost your savings and earn 4.35% APY with a Marcus by Goldman Sachs savings account, a rate that's 8x the national averagewhen signing up with Financhle. No fees, no minimum deposits, backed by the financial expertise of Goldman Sachs. Terms apply.
ⓒ 2024 Financhle. All Rights Reserved.